The 30-second summary
- Tirzepatide (Mounjaro, Zepbound) can reduce the absorption of oral contraceptive pills, especially during the four-week window after each dose increase.
- Semaglutide (Ozempic, Wegovy) does not carry the same labelled warning, but slowed gastric emptying can in theory affect any oral drug.
- The Eli Lilly label recommends adding a barrier method or switching to a non-oral contraceptive for four weeks after starting tirzepatide and four weeks after every dose increase.
Why this happens
GLP-1 medications slow gastric emptying. Tirzepatide slows it more aggressively than semaglutide. Oral contraceptive pills depend on consistent gastric absorption to maintain steady hormone levels. When the stomach empties more slowly than the dosing schedule assumes, peak hormone levels can drop below the threshold needed for contraception.
This was studied directly during Mounjaro/Zepbound's approval. In a pharmacokinetic study published as part of the FDA submission, a single dose of tirzepatide reduced the peak concentration of an oral contraceptive (a combined pill containing ethinyl estradiol and norgestimate) by about 59% for ethinyl estradiol and 55% for norelgestromin, and reduced overall exposure by roughly 20% and 23% respectively. (Eli Lilly, Mounjaro prescribing information, Section 7.1.)
These are not small numbers. They are large enough to make an unplanned pregnancy plausible for a woman relying on the pill while titrating tirzepatide.
What the label tells you to do
The Eli Lilly label is explicit:
Advise patients using oral contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.
This is the cleanest single sentence in the prescribing information for tirzepatide. Most women on Mounjaro or Zepbound climb through several dose escalations over their first six months, meaning the four-week barrier window applies more than once, every time the dose goes up.
What "non-oral contraceptive" means in practice
The label is essentially saying: switch from the pill to something that does not depend on gastric absorption. The options are:
- Hormonal IUD (Mirena, Liletta, Kyleena, Skyla): effective immediately, no GLP-1 interaction.
- Copper IUD (Paragard): hormone-free, no GLP-1 interaction.
- Contraceptive implant (Nexplanon): implanted in the upper arm, three years of protection.
- Vaginal ring (NuvaRing, Annovera): absorbs hormones through vaginal tissue, not the gut.
- Patch (Xulane): absorbs through skin.
- Injection (Depo-Provera): every three months.
A condom or diaphragm used reliably for the four-week window after each dose change is also acceptable per the label, though it requires perfect-use discipline.
What about semaglutide?
Semaglutide (Ozempic, Wegovy) does not carry the same explicit warning. The Novo Nordisk label notes that semaglutide can delay gastric emptying and "could affect the absorption of concomitantly administered oral medications," but the pharmacokinetic studies with oral contraceptives did not show a clinically meaningful reduction in effectiveness. (Novo Nordisk, Wegovy prescribing information, Section 7.)
For most women on semaglutide using oral contraception, no special precaution is required. If you are unsure, the safest answer is the same one: switch to a non-oral method or add a barrier. The downside of caution is minimal; the downside of an unintended pregnancy is not.
What this is not
This is not a fertility warning. It is the opposite. The pill becomes less reliable, not more. Women on tirzepatide who want to avoid pregnancy need a more reliable method than they may currently be using.
It is also not a reason to stop your GLP-1. It is a reason to update your contraception plan.
What to talk to your prescriber about
If you are on Mounjaro or Zepbound and currently use oral contraception, raise this at your next appointment. The conversation has three parts:
- Which method makes sense for me? An IUD, an implant, a ring, a patch, or a barrier method as a bridge.
- What timing? A hormonal IUD can be placed in a 20-minute office visit. A switch is rarely complicated.
- What if I'm already past one dose increase? A pregnancy test is reasonable. So is a frank conversation about the last four weeks.
For women already trying to conceive, the conversation is different: GLP-1s are not recommended in pregnancy at all, and the standard guidance is to stop the medication and wait at least two months before attempting conception. We have a separate article on pregnancy and GLP-1s.
What Steady does with this
If you log Mounjaro or Zepbound as your medication in Steady, the app surfaces this information in your medication detail view, not as a pop-up, but as a one-line note next to your dose escalation history. The day after a dose increase, you should see an in-app reminder that the four-week barrier window has started.
Sources
- FDA Prescribing Information, Mounjaro. Section 7.1, Oral Contraceptives. Label
- FDA Prescribing Information, Zepbound. Label
- FDA Prescribing Information, Wegovy. Section 7. Label
Medical disclaimer: This is one of the few topics in this hub that has a specific, label-based answer. Talk to your prescriber to confirm the right contraception plan for your body. See our full medical disclaimer.